Aveva Eyeing Hypertension, Pain Relief Categories For Transdermal Therapies
Executive Summary
A generic clonidine patch will be Aveva Drug Delivery Systems' first product launch following the company's divestiture by Elan
You may also be interested in...
Elan's $375 mil. acquisition of Sano brings two Phase III transdermal projects.
ELAN ACQUISITION OF SANO BRINGS TWO PHASE III TRANSDERMAL PROJECTS to Elan's development portfolio, the company said Dec. 15. Sano's highest profile project is a transdermal formulation of Bristol-Myers Squibb's anxiolytic BuSpar (buspirone), and the company also has a smoking cessation patch in Phase III.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials